Biohaven Pharmaceutical News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.11.21	Pfizer Inks Deal With Biohaven To Commercialize Rimegepant, Zavegepant, Outside The U.S. (RTTNews)
09.11.21	Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States (PR Newswire)
09.11.21	Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments (PR Newswire)
04.11.21	Biohaven To Report Third Quarter 2021 Financial Results And Recent Business Developments On November 9, 2021 (PR Newswire)
05.10.21	Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment (PR Newswire)
27.09.21	Biohaven's Verdiperstat Fails To Show Efficacy For Multiple System Atrophy Treatment; Stock Down (RTTNews)
09.08.21	Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments (PR Newswire)
29.07.21	Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race (PR Newswire)
28.07.21	Biohaven to Report Second Quarter 2021 Financial Results and Recent Business Developments on August 9, 202 (PR Newswire)
07.07.21	Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment (PR Newswire)
23.06.21	Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven (PR Newswire)
17.06.21	Biohaven Appoints Kishen Mehta to Board of Directors (PR Newswire)
27.03.21	Biotech Stocks Facing FDA Decision In April 2021 (RTTNews)
20.01.21	ACRS Soars On RA Trial Data, BHVN Disappoints In Alzheimer's Trial, GRTS Joins COVID-19 Vaccine Race (RTTNews)
10.09.20	Biohaven Pharma Advances Oral Formulations Of Zavegepant Into Human Studies (RTTNews)
07.08.20	Stock Alert: Biohaven Pharma Shares Up 8% (RTTNews)
22.07.20	AUPH Faces FDA In Jan, ARCT To Advance LUNAR-COV19 Vaccine, IFRX On Watch, All Eyes On ALEC (RTTNews)
09.04.20	Biohaven Pharma To Begin Phase 2 Trial Of Intranasal Vazegepant (RTTNews)
31.03.20	AMRN Loses Legal Fight, AKRO Awaits Big Day, JNJ's Covid-19 Vaccine Study In Sep (RTTNews)
30.03.20	Stock Alert: Biohaven Pharmaceutical Down 7% (RTTNews)
28.02.20	FDA Nod For BHVN's Drug, IBIO On Watch, SGMO Soars On Biogen Deal (RTTNews)
23.02.20	Biohaven Pharma (BHVN) Has A Pair Of Important Catalysts In Q1 (RTTNews)
11.02.20	ACST Plunges On Data Delay, MREO On Watch, AQST Faces FDA In Sep. (RTTNews)
10.02.20	Stock Alert: Biohaven Down 8% After Anxiety Drug Fails Late-stage Study (RTTNews)
22.11.19	Did This Stock Catch Your Eye? (BHVN) (RTTNews)
22.07.19	FDA Says No To BHVN, Detraxi Eyeing Solution For Blood Shortage, MRKR On Watch (RTTNews)
07.06.19	Pain, Pain Go Away - The Suicide Disease Drug Pipeline (RTTNews)
09.03.19	Did You Invest In These Biotech Stocks? (RTTNews)
23.01.19	Biohaven Gets FDA May Proceed Letter For Phase 3 Trial Of BHV-3241 For MSA (RTTNews)
04.12.18	GBT On Fast Track, GH In Good Health, For BHVN, It's All Gain, No Pain (RTTNews)
15.08.18	Keep An Eye On ATNM Today, PETQ Upbeat, MTFB To Face FDA In Feb (RTTNews)
19.06.18	CSBR Up 36% This Month, ZIOP Hit By Clinical Hold, Watch Out For SRPT Today (RTTNews)
19.06.18	Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million (PR Newswire)
13.06.18	Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region (PR Newswire)
05.06.18	Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual... (PR Newswire)
15.05.18	Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results (PR Newswire)
09.05.18	Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) (PR Newswire)
04.05.18	This Day That Year: Biohaven Pharma (RTTNews)
03.05.18	CONSOL Energy Announces Results for the First Quarter 2018 (PR Newswire)
23.04.18	BHVN In Focus, Fresenius Calls Off Deal To Buy AKRX, Good News For GUD (RTTNews)
23.04.18	Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain... (PR Newswire)
21.04.18	An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR…) (RTTNews)
19.04.18	Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles (PR Newswire)
05.04.18	Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference (PR Newswire)
03.04.18	Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer (PR Newswire)
26.03.18	Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine (PR Newswire)
18.03.18	An Ear To The Pharma: 11 Stocks To Watch This Week (RTTNews)
12.03.18	Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading... (PR Newswire)
07.03.18	In The Spotlight: Biohaven Pharma (RTTNews)
07.03.18	FDA Approves New HIV Drug, Mark Your Calendar For BHVN, Watch Out For ZFGN (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	175.00	2.88 %	K V
Sika	233.60	2.19 %	K V
Holcim	91.14	1.47 %	K V
Sonova Hldg	318.40	1.14 %	K V
Logitech Intl	83.02	0.95 %	K V
Zurich Insur Gr	539.20	-0.15 %	K V
Novartis	90.12	-0.16 %	K V
Kuehne+Nagel Int	206.20	-0.19 %	K V
Swisscom	506.00	-0.30 %	K V
Givaudan	3’854.00	-2.21 %	K V

Nachrichten zu Biohaven Pharmaceutical Holding Co Ltd Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten